Follow the people · Insider
Christopher P. Kiritsy
Christopher P. Kiritsy files insider transactions with the SEC as a director of Palvella Therapeutics (PVLA). We hold 1 disclosed purchase or sale filed since 22 September 2016, 1 of them in the last 90 days.
- Files forPVLA
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure4 September 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 December 2024 — 2 September 2026Director · Palvella Therapeutics (PVLA)6 Form 4 lines · source: SEC Form 4
- Filed 20 September 2016 — 2 December 2024Director · Pieris Pharmaceuticals (PIRS)15 Form 4 lines · source: SEC Form 4
- Filed 27 January 2022 — 15 September 2022Director · Htg Molecular Diagnostics (HTGM)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
23 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 313 shares of Palvella TherapeuticsSEC Form 44 September 2026Common Stock · traded 2 September 2026 · filed 4 September 2026
- ▼ sold on the open market 313 shares of Palvella TherapeuticsSEC Form 44 September 2026Common Stock · traded 2 September 2026 · filed 4 September 2026
- exercised options over 313 shares of Palvella Therapeutics (a derivative holding)SEC Form 44 September 2026Stock Option (Right to Buy) · traded 2 September 2026 · filed 4 September 2026
- was granted 3,000 shares of Palvella Therapeutics (a derivative holding)SEC Form 412 June 2026Stock Option (Right to Buy) · traded 10 June 2026 · filed 12 June 2026
- was granted 12,350 shares of Palvella Therapeutics (a derivative holding)SEC Form 411 June 2025Non-Qualified Stock Option (right to buy) · traded 10 June 2025 · filed 11 June 2025
- was granted 24,700 shares of Palvella Therapeutics (a derivative holding)SEC Form 417 December 2024Stock Option (right to buy) · traded 13 December 2024 · filed 17 December 2024
- was granted 500 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 49 December 2024Stock Option (right to buy) · traded 2 December 2024 · filed 9 December 2024
- was granted 40,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 423 June 2023Stock Option (right to buy) · traded 21 June 2023 · filed 23 June 2023
- ▲ bought on the open market 10,000 shares of Pieris PharmaceuticalsSEC Form 430 May 2023Common Stock · traded 25 May 2023 · filed 30 May 2023
- was granted 4,000 shares of Htg Molecular Diagnostics (a derivative holding)SEC Form 415 September 2022Stock Option (right to buy) · traded 15 September 2022 · filed 15 September 2022
- was granted 40,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 424 June 2022Stock Option (right to buy) · traded 22 June 2022 · filed 24 June 2022
- was granted 8,000 shares of Htg Molecular Diagnostics (a derivative holding)SEC Form 431 January 2022Stock Option (right to buy) · traded 27 January 2022 · filed 31 January 2022
- was granted 40,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 429 June 2021Stock Option (right to buy) · traded 25 June 2021 · filed 29 June 2021
- was granted 40,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 425 June 2020Stock Option (right to buy) · traded 23 June 2020 · filed 25 June 2020
- was granted 40,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 425 June 2020Stock Option (right to buy) · traded 23 June 2020 · filed 25 June 2020
- was granted 20,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 428 January 2020Stock Option (right to buy) · traded 25 January 2020 · filed 28 January 2020
- was granted 20,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 429 January 2019Stock Option (right to buy) · traded 25 January 2019 · filed 29 January 2019
- ▲ bought on the open market 5,000 shares of Pieris PharmaceuticalsSEC Form 417 September 2018Common Stock · traded 14 September 2018 · filed 17 September 2018
- was granted 20,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 429 January 2018Stock Option (right to buy) · traded 25 January 2018 · filed 29 January 2018
- exercised options over 5,000 shares of Pieris PharmaceuticalsSEC Form 49 May 2017Common Stock · traded 21 April 2017 · filed 9 May 2017
- exercised options over 5,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 49 May 2017Stock Option (right to buy) · traded 21 April 2017 · filed 9 May 2017
- was granted 20,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 430 January 2017Stock Option (right to buy) · traded 25 January 2017 · filed 30 January 2017
- was granted 30,000 shares of Pieris Pharmaceuticals (a derivative holding)SEC Form 422 September 2016Stock Option (right to buy) · traded 20 September 2016 · filed 22 September 2016
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.